IDEXX Laboratories, Inc. (IDXX)
NASDAQ: IDXX · Real-Time Price · USD
608.41
-10.51 (-1.70%)
At close: Mar 6, 2026, 4:00 PM EST
606.48
-1.93 (-0.32%)
After-hours: Mar 6, 2026, 6:29 PM EST
IDEXX Laboratories Stock Forecast
Stock Price Forecast
The 9 analysts that cover IDEXX Laboratories stock have a consensus rating of "Buy" and an average price target of $715, which forecasts a 17.52% increase in the stock price over the next year. The lowest target is $475 and the highest is $805.
Price Target: $715 (+17.52%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IDEXX Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $775 → $750 | Hold | Maintains | $775 → $750 | +23.27% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $850 → $800 | Buy | Maintains | $850 → $800 | +31.49% | Feb 5, 2026 |
| UBS | UBS | Hold Maintains $750 → $730 | Hold | Maintains | $750 → $730 | +19.98% | Feb 3, 2026 |
| BTIG | BTIG | Strong Buy Maintains $830 → $800 | Strong Buy | Maintains | $830 → $800 | +31.49% | Feb 3, 2026 |
| Barclays | Barclays | Buy Initiates $850 | Buy | Initiates | $850 | +39.71% | Dec 9, 2025 |
Financial Forecast
Revenue This Year
4.77B
from 4.30B
Increased by 10.83%
Revenue Next Year
5.18B
from 4.77B
Increased by 8.60%
EPS This Year
14.82
from 13.08
Increased by 13.33%
EPS Next Year
16.71
from 14.82
Increased by 12.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.9B | 5.4B | |||
| Avg | 4.8B | 5.2B | |||
| Low | 4.5B | 4.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 14.8% | 13.9% | |||
| Avg | 10.8% | 8.6% | |||
| Low | 5.6% | 2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 15.47 | 17.73 | |||
| Avg | 14.82 | 16.71 | |||
| Low | 14.03 | 15.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.2% | 19.6% | |||
| Avg | 13.3% | 12.7% | |||
| Low | 7.3% | 3.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.